Accessibility Menu
Cspc Pharmaceutical Group logo

Cspc Pharmaceutical Group(SEHK) 1093

Market CapHK$100.13BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1994)+4,577%
5 Year-20%
1 Year-20%
1 Month+8%
HK$8.80
+0.46%
+0.04Today
Cspc Pharmaceutical Group last closing stock price
MetricPriceDate
Last closeHKD 8.762026-08-17
Cspc Pharmaceutical Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.51%HKD 8.632026-08-10
1 month+8.15%HKD 8.102026-07-17
3 month+17.58%HKD 7.452026-05-19
Year to date+3.91%HKD 8.432025-12-31
1 year-20.07%HKD 10.962025-08-15
3 year+55.04%HKD 5.652023-08-18
5 year-20.36%HKD 11.002021-08-18
Since inception+4,577.33%HKD 0.191994-06-27

Cspc Pharmaceutical Group Financials at a Glance

Market Cap

HK$100.13BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥54.92B

Net Income (TTM)

CN¥8.19B

EPS (TTM)

HK$0.37

P/E Ratio

23.68

Dividend

HK$0.29

Beta (Volatility)

0.02 (Low)

Price

HK$8.80

Volume

17,142,000

Open

HK$8.75

Previous Close

HK$8.76

Daily Range

HK$8.63 - HK$8.89

52-Week Range

HK$6.53 - HK$11.63

Estimated Earnings Date

Aug 20, 2026

1093 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cspc Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a leading pharmaceutical company focused on the development, production, and distribution of a wide range of pharmaceutical products. With a strong presence in China and expanding operations globally, CSPC is dedicated to addressing various health conditions through innovative therapies.

Products and Services
  • Finished drugs for conditions like cancer, cardiovascular diseases, and neurological disorders
  • Active pharmaceutical ingredients (APIs) including antibiotics and vitamins
  • Functional foods and healthcare services to enhance overall well-being
Growth Outlook
  • Revenue of CNY 12.52 billion in Q4 2025, showcasing strong market demand
  • Net income increased to CNY 1.31 billion in Q4 2025, reflecting operational efficiency
  • Continued investment in R&D, with CNY 3.07 billion allocated in Q4 2025
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 50.67 billion, indicating robust growth
  • Net profit margin of 14.92% TTM, demonstrating effective cost management
  • Dividend yield of 3.31% TTM, providing attractive returns to shareholders
CSPC Pharmaceutical Group Limited operates in a competitive industry, yet it has established a solid reputation for quality and innovation. The company's diverse product portfolio addresses critical health issues, positioning it well for future growth. Recent financial performance highlights a strong revenue trajectory and profitability, supported by strategic investments in research and development. With a commitment to enhancing healthcare outcomes, CSPC is poised to capitalize on emerging opportunities in the pharmaceutical sector.
AI Generated • Jul 29, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

19,700

CEO

Lei Cai, PhD

Website

www.cspc.com.hk

Headquarters

Shijiazhuang, HE 050035, CN

1093 Financials

Key Financial Metrics (TTM)

Gross Margin

65.59%

Operating Margin

15.26%

Net Income Margin

14.92%

Return on Equity

11.47%

Return on Capital

11.43%

Return on Assets

8.16%

Earnings Yield

4.22%

Dividend Yield

3.34%

Payout Ratio

64.44%

Stock Overview

Market Cap

HK$100.13BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.52B

Volume

17.14M

Avg. Volume

99.00M

Financials (TTM)

Gross Profit

CN¥37.31B

Operating Income

CN¥9.31B

EBITDA

CN¥12.99B

Operating Cash Flow

CN¥10.71B

Capital Expenditure

-CN¥4.12B

Free Cash Flow

CN¥6.59B

Cash & ST Invst.

CN¥8.87B

Total Debt

CN¥641.38M

Cspc Pharmaceutical Group Performance Analysis

Cspc Pharmaceutical Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 35,975,851,1727.1%
20232023-12-31CNY 34,752,307,458-3.4%
20242024-12-31CNY 31,452,524,840-9.5%
20252025-12-31CNY 28,204,093,089-10.3%
Cspc Pharmaceutical Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-309.2%
Q42024-12-31-21.0%
Q22025-06-300.4%
Q42025-12-31-3.8%
Cspc Pharmaceutical Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.595.2%
20232023-12-31CNY 0.55-8.0%
20242024-12-31CNY 0.40-26.9%
20252025-12-31CNY 0.37-7.8%
Cspc Pharmaceutical Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-308.3%
Q42024-12-31-57.7%
Q22025-06-30100.0%
Q42025-12-31-45.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CN¥12.52B

-16.7%

Gross Profit

CN¥8.21B

-23.3%

Gross Margin

65.57%

N/A

Market Cap

HK$100.13BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$5.08M

N/A

Employees

19,700

N/A

Net Income

CN¥1.31B

-53.9%

EBITDA

CN¥2.09B

-50.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CN¥8.87B

-32.3%

Total Debt

CN¥641.38M

-9.3%

Accounts Receivable

CN¥9.55B

-5.7%

Inventory

CN¥3.09B

-10.5%

Long Term Debt

CN¥180.77M

+68.9%

Short Term Debt

CN¥460.42M

-23.2%

Return on Assets

8.16%

N/A

Return on Invested Capital

10.67%

N/A

Free Cash Flow

CN¥2.00B

-4.8%

Operating Cash Flow

CN¥2.76B

-4.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,754.42-0.00%
^DJIDJI
$53,461.25-0.01%
^IXICNASDAQ
$26,653.02-0.00%
BTCBitcoin
$64,341.00+0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.61-0.02%
SPCXSpace Exploration Technologies
$146.23+0.04%
IPSTIp Strategy
$7.39+2.36%
NVDANvidia
$225.01-0.00%

Questions About 1093

What is the current price of Cspc Pharmaceutical Group?

Cspc Pharmaceutical Group is trading at HK$8.80 per share.

What is the 52-week range for Cspc Pharmaceutical Group?

Over the past 52 weeks, Cspc Pharmaceutical Group has traded between HK$6.53 and HK$11.63.

How much debt does Cspc Pharmaceutical Group have?

As of the most recent reporting period, Cspc Pharmaceutical Group reported total debt of CN¥714.08M.

How much cash does Cspc Pharmaceutical Group have on hand?

Cspc Pharmaceutical Group reported CN¥5.87B in cash and cash equivalents in its most recent financial results.

What is Cspc Pharmaceutical Group’s dividend yield?

Cspc Pharmaceutical Group currently has a dividend yield of 3.34%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services